Our leadership team is a highly successful and uniquely experienced group of clinicians, scientists, investment professionals, and health policy experts.
Our focus: deliver novel antiviral treatments to the right patients at the right time, to significantly reduce morbidity, mortality, and costs associated with viral infections.
Altesa’s world-class scientific founders and team have significantly benefited human health against the two greatest pandemics of the past 100 years. Specifically, Altesa’s DRIVE/Emory partners invented some of the most acclaimed, lifesaving, and impactful antiviral drugs worldwide, including emtricitabine (Emtriva®), which combats HIV/AIDS, and molnupiravir (Lagevrio®), which prevents hospitalization and death from COVID-19. Altesa’s clinical, regulatory, and scientific teams also have helped develop and market critical antivirals like brincidofovir (Tembexa®), to treat smallpox, and enfuvirtide (Fuzeon®), the first HIV fusion inhibitor to treat HIV/AIDS.
Brett P. Giroir, MD
CEO and Acting Chief Medical Officer
- Former US Assistant Secretary for Health and Admiral, USPHS
- Former Acting FDA Commissioner
- Former CEO, ViraCyte (now AlloVir)
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
Gary Ferguson, MD
- Clinical Professor of Medicine, Michigan State University
- Director Emeritus, Pulmonary Research Institute of Southeast Michigan
- Former Director of the Emphysema/COPD program, National Jewish Medical Center
Partners / Collaborators
Altesa has an innovative relationship with Drug Innovation Ventures at Emory (DRIVE), formed by Emory University, to discover and advance drug candidates for critical global viral diseases. DRIVE is both a key scientific collaborator and a founding shareholder of Altesa.
Altesa’s DRIVE/Emory lead scientists, George R. Painter, PhD, and Dennis C. Liotta, PhD, are Altesa scientific co-founders and serve on the firm’s Scientific Advisory Board. Drs. Painter and Liotta were instrumental, respectively, in the successful commercialization of molnupiravir, which combats COVID-19, and emtricitabine, which combats HIV/AIDS.
The unprecedented partnership agreement between Altesa and DRIVE led to the licensing of a late-stage, preclinical, antiviral drug (ALT-2023) in January 2022. ALT-2023 is a broad-spectrum nucleoside analog that is active against most enteroviruses and flaviviruses, including rhinovirus and hepatitis C. Altesa has a unique, preferred relationship with DRIVE/Emory, giving Altesa exclusive access to up to five additional DRIVE molecules to combat other deadly viruses.